NRX Pharmaceuticals (NRXP) just unveiled an update.
A company has announced through a press release that it has agreed on a non-binding term sheet, which could provide up to $7.5 million to refinance existing toxic debt, with a potential for an extra $22.5 million in additional funding. The total accessible capital could reach $30 million, but this is contingent upon successful due diligence and the finalization of binding agreements.
For a thorough assessment of NRXP stock, go to TipRanks’ Stock Analysis page.
